PT  - JOURNAL ARTICLE
AU  - Müller, Michael
AU  - Volzke, Johann
AU  - Subin, Behnam
AU  - Müller, Silke
AU  - Sombetzki, Martina
AU  - Reisinger, Emil C.
AU  - Müller-Hilke, Brigitte
TI  - Single-Dose SARS-CoV-2 Vaccination With BNT162b2 and AZD1222 Induce Disparate Th1 Responses and IgA Production
AID  - 10.1101/2021.09.17.21263726
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.17.21263726
4099  - http://medrxiv.org/content/early/2021/09/21/2021.09.17.21263726.short
4100  - http://medrxiv.org/content/early/2021/09/21/2021.09.17.21263726.full
AB  - While vaccination programs against SARS-CoV-2 are globally ongoing, disparate strategies for the deployment of spike antigen show varying effectiveness. In order to explore this phenomenon, we sought to compare the early immune responses against AZD1222 and BNT162b2. SARS-CoV-2 seronegative participants received a single dose of either vaccine and were analyzed for immune cell, effector T cell and antibody dynamics. AZD1222 induced transient leukopenia and major changes among innate and adaptive subpopulations. Both vaccines induced spike protein specific effector T cells which were dominated by Th1 responses following AZD1222 vaccination. A significant reduction of anti-inflammatory T cells upon re-stimulation was also restricted to AZD1222 vaccinees. While IgM and IgG were the dominant isotypes elicited by AZD1222, BNT162b2 led to a significant production of IgG and IgA. Our results suggest that the strategy for spike antigen delivery impacts on how and to what extent immune priming against the main SARS-CoV-2 antigen proceeds.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financially supported by the Federal State of Mecklenburg-Western Pomerania via the Sondervermoegen des MV Schutzfonds Saeule Gesundheit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the Rostock University Medical Center under the file number A 2020-0086. Written informed consent was provided by all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article (and its supplementary information files).